Data coverage, completeness and provenance for INVEX THERAPEUTICS LTD in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-27T02:20:00. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.1000 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.1000 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.1000 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.1000 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.1200 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/IXC/prices · Price parameters and adjustment semantics
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
Website: https://www.invextherapeutics.com · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/IXC/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 18 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 20 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 19 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 18 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 18 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/IXC
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/IXC/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/IXC/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/IXC/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/IXC/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/IXC
Free tier — instant API key. Built for AI agents.